To the Editor:
A recent demographic and health survey was performed in Cameroon in 2004 that showed an HIV-1 seroprevalence rate of 5.5% in the general population. 1 In Yaound2, the capital city of Cameroon, HIV-1 prevalence is as high as 10% among pregnant women attending antenatal centers. 2 Since the year 2000, a public health pilot program for the prevention of mother-to-child transmission started providing a single dose of the nonnucleoside reverse transcriptase (RT) inhibitor, nevirapine (NVP), to pregnant women who were diagnosed as HIV-1 positive in a maternity ward in Yaound2. 2 This program is now scaled to at least 60% of health districts of the country. 3 One of the main portals of antiretroviral (ARV) entry in Cameroon is via the HIV-1 prevention of mother-to-child transmission program. To date, no information is available on ARV resistance in this sentinel population. The present study aimed to investigate whether genetic polymorphisms were present in RT and protease (PR) of HIV-1 genes at positions affecting the susceptibility to ARV and to evaluate baseline drug resistance among HIV-1Yinfected pregnant women, naive to NVP in Yaound2, Cameroon, where HIV-1 non-B subtypes predominate.
After informed consent was obtained, HIV-1Ypositive pregnant women who were willing to participate in the study were included and interviewed for ARV history. Blood samples (2 Â 5 mL) were drawn by venous puncture on EDTA-treated tubes. CD4 + T-lymphocyte enumeration was performed by flow cytometry with a FACSCount (BectonDickinson, San Jose, CA) and plasma viral load was quantitated by bDNA (Bayer Diagnostics, Paris, France). Viral RNA for the genotypic resistance study was extracted from 1 mL of plasma by using the Qiagen viral RNA extraction mini kit (Qiagen, Inc., Chatsworth, CA) as recommended by the manufacturer. The RT gene (codons 1Y255) and PR gene (codons 1Y99) were amplified by using the primers MJ3/MJ4 and Prot1FW/Prot1RV, 4Y6 respectively. These first polymerase chain reaction (PCR) were followed by nested PCR with primers A35/NE1 for RT and Prot2FW/Prot2Rev 4, 7 for PR. PCR products were sequenced on both strands by Genome Express (Meylan, France) using the BigDye Terminator v3.1 Cycle Sequencing Kit on a 3730xl DNA analyzer (Applied Biosystems, Foster City, CA). Prot2FW/Prot2Rev and A35/NE1 primer sets were used for the PR and RT, respectively. Sequences were manually corrected by using the Ceq2000 (Beckman Coulter) software using the HIV-1 HXB2 (GenBank Acc. Number: K03455) sequence as template. Genotypic drug resistance interpretation was performed according to the latest version (September 2005) of the French Agence Nationale de Recherche contre le Sida et les H2patites algorithm (http://www. hivfrenchresistance.org/).
Between 2001 and 2004, a total of 110 HIV-1Ypositive pregnant women consented to participate in the study. They were all ARV therapy-naive before the index pregnancy. One hundred ten amino acid sequences were obtained in the PR gene and 109 in the RT gene. In this report, we considered only samples with complete sequences for both strands in the PR and RT genes. Overall, 96 ARV therapy-naive pregnant women whose HIV-1 were fulllength sequenced in both PR and RT genes were analyzed. Age at inclusion was 27 years on average (range, 16Y41 years). HIV-1 status was known for an average of 7 months (range, 3Y12 months). The mean T-lymphocyte count was 365 (range, 9Y962 cells/2L) and viral load was, on average, 4.8 log 10 RNA copies/mL (range, 1.7Y5.7 log 10 RNA copies/mL). Phylogenetic analysis of the 96 PR and RT sequences, together with Basic Local Alignment Search Tool search, revealed a high genetic diversity in both genes. Almost all known HIV-1 subtypes were found, with CRF02-AG representing, however, 63 of 96 (65.6%) sequences in PR and 56 of 96 (58.3%) in RT genes. Other circulating recombinant forms were marginally found: CRF11 (6.2% in PR and 5.2% in RT), CRF14 (5.2% in PR), and other subtypes represent 14 of 96 sequences in PR and 22 of 96 sequences in RT. Complex recombinant forms were encountered more often in the RT genes, where they represent up to 26% (25/96). Sequence analysis for genotypic drug resistance in the RT gene revealed no major mutations associated with HIV-1 ARV resistance. One sample (M4587N, HIV-1/F2 Beckman-Coulter, Nyon, Switzerland) presented the L210W and T215S amino acid mutations. These mutations confer a possible resistance to the nucleoside RT inhibitors, zidovudine and stavudine, and to the nucleotide analog RT inhibitor, tenofovir. In the PR gene, all of the 96 sequences analyzed harbored 2 mutations or more at positions associated with a lower susceptibility to PR inhibitors in subtype B HIV-1 strains (Fig. 1) . More than 87% of the sequences harbored 5 to 9 mutations. Minor amino acid substitutions K20I, M36I, R41K, and H69K were found at 79%, 99%, 86%, and 95% frequencies, respectively. One sample (M3988N) showed the mutation N88S, conferring resistance to the PR inhibitor nelfinavir. Overall, 1 (M3988N, 1.04%) of 96 samples we analyzed in the RT and PR presented a major HIV-1 drug resistance mutation in the PR gene (N88S) that confers resistance to the PR inhibitor, nelfinavir. In the present study, we have shown that HIV-1 genetic diversity in both PR and RT genes is very high in viruses circulating in seropositive pregnant women in Yaound2, confirming previous findings from the same country but targeting a mixed population of men and women. 8, 9 Genotypic drug resistance analysis of the pol gene uncovered no major drug resistance mutation but one (M3988N) in both RT and PR, despite the great genetic diversity observed. This lack of major drug resistance mutation is consistent with an ARV-naive population, in an area like Cameroon, where mass antiYHIV-1 drugs are of relatively recent introduction. In the PR gene, the high genetic diversity observed seems to be correlated to a high degree of polymorphism at positions known to be associated with drug resistance in subtype B HIV-1. This observation was repeatedly reported in various studies on samples obtained from Africa and, to a lesser extent, from southeast Asia.
10,11 The implication of these polymorphisms at key amino acid positions in the PR gene remains a concern for long-course anti-PR treatment of HIV-1Yinfected patients in southern countries.In the course of the present study, a small group of 10 women who already experienced NVP in a previous pregnancy was screened as well. Analysis of corresponding samples did not reveal either the presence of NVP-related mutations or related to other ARV. It should be mentioned, however, that the time between the 2 pregnancies was always greater than 20 months for the 10 women. Hence, single-dose NVP-associated mutations fade up in the plasma by approximately 18 months after drug application, as previously reported.
12,13 These findings also emphasize the urgent need for genotypic drug resistance interpretation algorithms adapted to nonsubtype B HIV-1 strains.Our present data indicate that less than 1% of HIV-1Ypositive, ARV-naive pregnant women in Yaound2 carried viruses with major genotypic drug resistance mutations. It would be very informative to repeat such a study to evaluate the incidence of HIV-1 drug resistance mutations among ARV-naive and ARVexperienced pregnant women in Cameroon and the impact of a greater availability of ARV to other subpopulations. Antiretroviral treatment for patients who have failed previous regimens is frequently complex; it includes a high number of drugs, doses, and pills, and is inconvenient for HIV-infected patients.
1,2 Protease inhibitors (PIs) are frequently included in these regimens because the nonnucleosides are no longer useful because of development of high-level cross-resistance. The administration of most PIs requires multiple daily doses and a high number of pills, but development of once-daily PI-containing combinations has been achieved recently.
3Y5 Atazanavir (ATV) is a new, potent, safe, and well-tolerated azapeptide PI that can be dosed once daily and has shown a good efficacy, tolerability, and convenience profile in clinical trials of PI-experienced patients. 6Y8 However, there is little information about its efficacy in heavily antiretroviral-experienced HIV-infected patients. The administration of ATV, together with other drugs approved for once-daily dosing, can allow regimens to be fully administered once a day. We evaluated the efficacy and safety of ATV-based rescue regimens, in combination with drugs approved for oncedaily administration, given in a clinical setting.
We describe a prospective cohort study of multiexperienced patients who initiated salvage therapy at a single center in Madrid, Spain. All antiretroviralexperienced HIV-seropositive patients (n = 56) who initiated a rescue highly active antiretroviral therapy with an ATVbased regimen between March 2003 and September 2004 were included in this analysis. ATV was administered through an early access program for the drug in Spain. Treatment-experienced patients with 2 consecutive viral load determinations above 1000 copies/mL were included. CD4 cell counts and HIV-1 RNA plasma levels, as well as blood and chemistry analyses, were determined at baseline and every 12 weeks thereafter. The primary end point was the virologic outcome, measured by variation in plasma HIV RNA levels and the proportion of patients with HIV RNA level G50 copies/mL, at month 12. Secondary objectives included immunologic response and safety. We adopted a 5% significance level for all tests. Analyses were performed using statistical software (version 11.0; SPSS, Chicago, IL).
Demographics and baseline characteristics are shown in Table 1 . Most patients were young men (71%), former injection drug users (65%), and severely pretreated. Patients were receiving their 10th line of antiretroviral therapy during a median of almost 4 years, and the median number of prior taken drugs was 9. Most patients (91%) had failed with at least one PI, and 69% had received 2 or more PIs. Other drugs included in the combination regimens were didanosine (ddI) + tenofovir disoproxil fumarate (TDF) (62.5%), lamivudine (3TC) + TDF (16%), ddI + 3TC (12.5%), ddI + 3TC + TDF (7%), and efavirenz + TDF (2%). Almost half of the patients (48%) were on Bdrug holidays[ (ie, discontinuation of treatment because of lack of virologic response with prior regimens). Median HIV RNA and CD4 cell count (interquartile range, IQR) values at 6 and 12 months were 1.8 log 10 (1.7Y3.08) and 411 cells/2L (237Y573), and 1.8 log 10 (1.7Y2.65) and 325 (184Y541) cells/2L, respectively. Proportion of patients achieving HIV RNA G50 copies/mL at the same time points were 46% and 48%, respectively. After 12 months, data from 46 patients were available for analyses. From baseline to month 12, median CD4 cell count change was +68 cells/2L, and the median viral load decrease was 2.5 log 10 .
The major finding of this study is that even if management of HIVinfected patients who have experienced prior virologic failure is challenging and often not successful, nowadays, pretreated patients in need of rescue therapies can also benefit from simple regimens, at least in the short-term. In this cohort, all patients received a oncedaily regimen with a low pill burden and the initial virologic decline was deeper than expected. At 12 months, almost half of our patients had a viral load G50 copies/mL, a percentage that is comparable with the results from a 48-week rescue trial in which 38% of patients reached G50 copies/mL when included on ATV/ritonavir (RTV) combination regimens. 8 In this trial, antiretroviral-experienced patients who had had virologic failure on 2 or more highly active antiretroviral therapy regimens were randomized to receive ATV (boosted with RTV or in combination with saquinavir) or lopinavir/RTV. 8 Median prior exposure to any PI, nonnucleoside reverse transcriptase inhibitor, and nucleoside reverse transcriptase inhibitor were 2.5, 1.5, and 5.1 years, respectively. A quarter of patients included in the ATV/RTV arm had 4 or more PI mutations. 8 In our cohort, patients were receiving (median) their 10th line of antiretroviral therapy when they started the ATV-containing regimen, and the median number of mutations was high in both the retrotranscriptase (10, IQR: 5Y15) and protease (5, IQR: 4Y8) genes. Twenty-five percent of patients had key mutations in the protease gene. TDF was the most frequently used retrotranscriptase inhibitor because many patients were naive for this drug. DDI plus TDF combination, which was administered to almost two thirds of the patients, is no longer recommended because of a possible deleterious effect on CD4 reconstitution. 9 Despite these facts, the virologic responses were good and a subsequent increase in the CD4 cell counts was observed.
Although this is an observational, clinical cohort study with a limited number of patients, and we cannot exclude the possibility that our results were distorted by residual confounding or unmeasured factors, it shows that antiretroviralexperienced HIV-infected patients may also benefit from simple regimens with low pill burden administered once daily, and can achieve a sustained immunovirologic response. Further studies are needed to confirm these observations, to define the best scenario for these oncedaily combinations, and to optimize the most effective therapeutic measures in this population. To the Editors:
Fernando Dronda
In recent years, a major improvement in the convenience of antiretroviral regimens was observed with a significant impact on the daily routine life of people living with HIV/AIDS (PLWHA).
The reduction in number of doses is one of the most crucial improvements recently achieved. 1 Simplification is thought to be a major strategy to improve or sustain adherence of people taking antiretroviral medications. 2, 3 However, studies on HIV-infected people demonstrated a clear efficacy of the reduction of doses in terms of improving drug adherence. Moreover, preferences of PLWHA focus on various components of the regimen convenience, especially tolerability of drugs and visible adverse events.
From July to September 2005, we conducted a survey on PLWHA investigating preferences regarding antiretroviral drugs. A questionnaire was posted on a frequently accessed Web site of one of large Italian not-for-profit nongovernmental organizations (NGOs) operating in the field of HIV/AIDS, whose mission is specific on the impact of HIV therapy on PLWHA (Nadir Onlus Foundation Web site, accessible at http://www.nadironlus.org; the site receives more than 40,000 hits per month). The same questionnaire was administered face-to-face by trained interviewers to PLWHA attending 6 Italian clinical centers.
The respondents were asked the following: (1) type of highly active antiretroviral therapy (HAART); (2) number of previous antiretroviral schemes; (3) number of daily doses; (4) preferred type of antiretroviral formulations; (5) self-reported missed doses of antiretrovirals; (6) problems related to therapy; (7) modalities on seeking information on antiretroviral drugs; and (8) sharing or influencing the choice of therapy with the physician. To investigate the preferences on the type of formulation of antiretrovirals, the subjects were asked whether they would prefer to have a simplification of therapy; if the answer was yes, the subjects were asked whether they would prefer fewer pills or fewer doses daily (no other answers were allowed). Nonadherent people were defined as those who admitted to having missed at least 1 dose in the previous week.
Four hundred sixteen people completed the questionnaire (229 via the Web and 187 during a face-to-face interview). Of these, 341 (82%) were taking HAART. Mean age was 32 years (SD, 8.5); 28% were women and 32% were HCV/HIV coinfected. Less than 2% were missing answers.
We observed some differences in people who participated in the survey via the Web versus people filling in the questionnaire during a face-to-face interview. People participating via the Web were more often men (77% vs 66%; P = 0.002), were more frequently taking at least a second regimen (78% vs 60%; P G 0.0001), were taking a once-daily regimen (22% vs 13%; P = 0.006), and were more often seeking information on therapy (88% vs 67%; P G 0.0001).
More than 35% of respondents taking HAART reported taking zidovudine plus lamivudine; more than 30%, tenofovir; 22%, efavirenz; 18%, nevirapine; 19%, lopinavir/ritonavir; and 10%, atazanavir. Thirty percent were taking their first HAART regimen; 23%, the second regimen; 17%, the third; and 30% were taking their fourth or more. Eighteen percent of the study population were taking a once-daily regimen; 70%, a twice-daily; 11%, a thrice-daily; and 1%, a more-than-thrice-daily scheme. More than 90% would agree to simplify therapy: 51.6% would like a reduction of the daily pill number, and 39.4% a reduction in number of daily doses (9% of respondents did not answer).
Twenty-five respondents (7.3%) were self-reported to be nonadherent.
No differences on the rate of nonadherent respondents were found between respondents taking a once-daily regimen and those taking a twice-daily scheme. However, among respondents taking a twice-daily regimen, 13 (72.2%) of 18 who were self-reported to be nonadherent would prefer a reduction of number of doses compared with 87 (43.9%) of 198 adherent respondents (odds ratio [OR], 3.31; 95% confidence interval [CI], 1.14Y9.67; P = 0.02). The risk of nonadherence was higher for people taking the third or more regimen when compared with people taking the first or second antiretroviral scheme (OR, 5.09; 95% CI, 1.86Y13.91; P = 0.001); the risk was also higher for those reporting body changes (OR, 2.16; 95% CI, 0.99Y4.88; P = 0.055) and for those preferring a reduction of doses than for those preferring less daily pills (OR, 2.4; 95% CI, 0.996Y6.02; P = 0.045).
One hundred fifty-four respondents (37%) reported to have some degree of problem with therapy. Of these, 42% identified the adverse events as the main problem related to therapy; 32%, the body changes; 24%, too much pills; and only 2%, too many doses.
Seventy-eight percent of respondents seek information on antiretroviral drugs (73% from a physician, 65% from the Web, 36% from NGOs fighting HIV/ AIDS, and 30% from media).
Eighty percent of respondents reported to have agreed with their physician regarding the choice of antiretroviral therapy. However, only 45% of respondents declared to have Binfluenced[ this choice. At multivariable analysis, respondents who influenced the choice of therapy were more likely to have completed the questionnaire via the Web (hazards ratio [HR], 1.65; 95% CI, 1.03Y2.63; P = 0.03), to seek information on antiretroviral drugs (HR, 2.54; 95% CI, 1.36Y4.74; P = 0.003), and take a once-daily regimen (HR, 1.57; 95% CI, 1.05Y2.35; P = 0.03).
From the present survey, the main concerns of PLWHA taking HAART are related to tolerability of drugs and to body changes. The reduction of number of doses seems to be a major issue only for a small proportion of respondents. However, a significant rate of respondents taking twice-daily regimens and preferring a reduction of daily doses were those who self-reported as nonadherent. In these patients, the simplification of therapy may represent a crucial strategy to achieve the best results in terms of adherence improvement.
Simpler regimens may increase satisfaction with therapy. However, advantages in terms of adherence to drugs are probably influenced by a combination of several attributes of the regimen complexity, mainly including tolerability, visible adverse events, and number of pills.
People seeking information on antiretroviral therapy and those with a more active role in the patient-physician relationship have the highest probability to have more convenient regimens.
Although the population filling in a questionnaire via the Web is different in some characteristics than people filling in a face-to-face survey, we think that, in the future, the use of the Internet for such a purpose has a lot of potential.
Rita Murri* Simone Marcotullio.
Piergiorgio LupoliFilippo von Schloesser.
when used for the first time selects viral mutations associated with resistance to nonnucleoside reverse transcriptase inhibitors (NNRTIs).
1 Selection of genotypic resistance is more common if maternal viral load is high, CD4 count is low, tends to be related to viral subtype, and can generally be detected even if other short-course prophylaxis drug regimens are given as well. 2, 3 However, the in vivo consequence of repeat use of sdNVP for selection of genotypic resistance has not been described. Repeat use may occur in a single pregnancy in the case of false labor or, more importantly, in subsequent pregnancy among women who previously received nevirapine (NVP) prophylaxis in a prior pregnancy. In either case the development of genotypic resistance may compromise the efficacy of sdNVP prophylaxis to reduce transmission, and it has important policy implications for this widely implemented public health practice. 4 In the setting of a prospective study, we assessed whether repeat use of sdNVP is associated with increased detection of NNRTI resistance mu-tations among HIV-positive women after delivery.
Blood samples collected 6 weeks after delivery were selected from 47 HIV-positive women followed as part of the Zambia Exclusive Breast-feeding Study 5 conducted in Lusaka, Zambia. Twenty-three women were identified as repeat users. Fifteen of these were known to have taken sdNVP in their prior pregnancy and received it for a second time in the index pregnancy (the prior pregnancy for 12/15 women occurred while enrolled in the Zambia Exclusive Breast-feeding Study, the others occurred in an earlier study at the same site). The mean time between the prior delivery and the index delivery was 18 months (median 16 months, range 11Y27). Eight women were identified who consumed two 200-mg NVP tablets before delivery, in all cases due to false labor. The median interval between the 2 doses was 2 days. A similar number (n = 24) of women who took NVP only once for the first time in the index pregnancy were selected for comparison with the repeat users. These women were randomly selected from the cohort matched as closely as possible to the repeat users by baseline viral load.
HIV RNA was extracted and amplified from stored plasma samples (2/49 selected samples could not be amplified). Codons 1 through 335 of the reverse transcriptase (RT) gene were sequenced using the ViroSeq HIV-1 Genotyping system version 2.0 (Applied Biosystems, Foster City, CA), analyzed on a genetic analyzer (model 3100, ABI PRISM), and assembled with the use of version 2.5 of the ViroSeq HIV-1 Genotyping system for the mutations associated with resistance to NNRTI. All samples were subtype C except one that was subtype G based on pol sequence. CD4 counts (FACSCount system, BD Immunocytometry Systems, San Jose, CA) and viral load (Roche Amplicor version 1.5, Roche, Branchburg, NJ) were measured at baseline during the index pregnancy (median 10 weeks before delivery).
RT mutations associated with high-or intermediate-level of NVP resistance were detected among 14 (29.8%) of 47 maternal samples tested. The prevalence of resistance mutations was similar regardless of prior history of NVP exposure. Genotypic resistance was detected among 33.3% of women taking sdNVP for the first time, 25.0% of women taking 2 doses in a single pregnancy, and 26.7% of women taking it for a second time within a subsequent pregnancy (P = .86, Table 1 ). The most common resistance mutations were K103N ), and the distribution of specific mutations was similar between the groups. There were no significant differences between the groups in time of blood sampling for resistance testing (mean 43 days postdelivery among first time users, 46 days among repeat users in the same pregnancy, and 40 days among repeat users in a second pregnancy).
Baseline viral load and CD4 count measurements were not significantly different between the groups. The mean HIV RNA copy number (CD4 count) was 4.50 (340) among first-time users, 4.70 (418) among repeat users in the same pregnancy, and 4.18 (316) among repeat users in a second pregnancy. After adjustment for baseline viral load, CD4 count, and time of blood sampling in a multivariable logistic regression model, there continued to be no increased detection of intermediate-or high-level NVP resistance in second pregnancies relative to first pregnancies [odds ratio (OR) = 1.06; 95% confidence interval (CI) 0.2Y5.2].
The mutations associated with intermediate-and high-level resistance to NVP were strongly correlated with baseline viral load, and there was a trend, albeit weaker, in the same direction with low CD4 count ( Table 1) . Each log increase of baseline viral load was associated with increased likelihood of genotypic NVP resistance (OR 4.00; 95% CI 1.1Y15.2). A relatively common variant was K166R (8/47), which has not been associated with NNRTI resistance and may not be related to sdNVP exposure; its detection was not correlated with baseline viral load or CD4 count.
Our preliminary data suggest that there is no increase in the detection of viral mutations associated with NNRTI resistance when sdNVP is taken for a second time in a subsequent pregnancy. Although we were able to assemble a unique population of repeat users to compare to first-time users matched by viral load, sample size is small, and the results should be confirmed in larger studies. Because our data are based on population sequencing of detectable resistance mutations at 6 weeks postdelivery, we may have missed other possible changes in the dynamics of viral resistance. Sequential measurements over time and quantification of low-level mutants may provide a more sensitive indicator of the development of resistance mutations with repeat use of NVP. The strong correlation we observed between viral load and genotypic resistance also cautions against uncrit-ical comparisons across studies because the proportions of women with high viral loads may differ substantially between study populations.
